^
23d
transcendIT-101: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=188, Active, not recruiting, Ascendis Pharma Oncology Division A/S | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • resiquimod SR (TransCon TLR7/8 Agonist)
1m
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
12ms
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • resiquimod SR (TransCon TLR7/8 Agonist)
1year
Enrollment open • Combination therapy • Surgery • Metastases
|
Keytruda (pembrolizumab) • resiquimod SR (TransCon TLR7/8 Agonist)
over1year
Degradable hydrogel for sustained localized delivery of anti-tumor drugs. (PubMed, J Pharm Sci)
Resiquimod, a TLR7/8 agonist, and axitinib, a vascular endothelial growth factor tyrosine kinase inhibitor, were chosen as anti-cancer drugs. In summary, TransCon Hydrogel technology allows localized sustained-release drug delivery for cancer therapy enabling high local drug concentrations while at the same time ensuring low systemic drug exposure over weeks with a single injection, which may improve the therapeutic index and improve efficacy, while minimizing systemic adverse events. A hydrogel prodrug of resiquimod, TransCon TLR7/8 agonist, is currently being investigated in clinical trials of patients with solid tumors (NCT04799054).
Journal
|
Inlyta (axitinib) • resiquimod (STM-416) • resiquimod SR (TransCon TLR7/8 Agonist)
2years
Enrollment change • Combination therapy • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • resiquimod SR (TransCon TLR7/8 Agonist)